Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd
The Agreement Expands the Companies’ Strategic Alliance STOCKHOLM, 7 May, 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the Korean pharmaceutical company PharmaResearch Products Ltd. (“PRP”) will finance the development of PXL01 for use to prevent fibrosis after spinal surgery. In return PRP received a global commercial license of PXL01 for the use in this indication. This license is the first step towards broadening the indications for PXL01.Promore Pharma AB today announced that PRP will fully finance the development of